Wednesday, 28 March 2012

March:Unrelated blogger comments 2

Sometimes you what to say something that is unrelated to the threads.
This is a spot for You. (This post may move around abit)

If you do not see you comment appear, it has been spammed by Google. There is an offensive word, term in there, reword and it should repost

12 comments:

  1. The Vitamin D tablets I take are D2, not D3.

    The Journal of Clinical Endocrinology & Metabolism November 1, 2004 argued that Vitamin D2 is much less effective than Vitamin D3 in humans, however, researchers from Boston University have reported in 2008 that both forms are equally effective at maintaining 25-hydroxyvitamin D status.

    I take 2000IU of D2 everyday, and I do get a lot of natural sunshine too when possible.

    Should I worry about my meds not being D3? My dad buys me the D2 and he says I shouldn't be so pedantic.

    ReplyDelete
  2. Re: "vD2 vs. vD3"

    Please see previous post: http://multiple-sclerosis-research.blogspot.co.uk/2011/07/vitamin-d2-or-d3.html

    If possible have your vD levels measured and adjust your dose accordingly.

    ReplyDelete
  3. Posting in the "unrelated comments section, hopefully. I have been endeavouring to clarify whether BG12 is immunosuppressive or immunomodulatory?
    Can anyone enlighten me?

    ReplyDelete
  4. On the topic of BG-12, what exactly is BG-12's mechanism of action on the immune system? My MS nurse tells me that it's an antioxidant. I get the feeling that BG-12 will be prescribed in addition to the injectables and Tysabri, instead of replacing them.

    ReplyDelete
  5. That BG12 can suppress the relapse rate by 50% suggests that has immunosuppressive activity but in experimental models is is not that great as an immunosuppressive. But it must be doing something, as is was used in psorasis for many years. There is evidence that Nrf2 is a target for BG12 and this transcription factor controls a the production of a number of genes that make anti oxidatant proteins. It may therefore have the capacity to slow nerve damage and so may modulate the damaging environment. But it is all words immunomodulator can down regulate (suppress i.e immunosuppressive) or up regulate the immune response.

    Therefore it has the potential to do more than just suppress relapses.

    ReplyDelete
  6. Re: "BG12"

    BG12 is a metabolite, dimethyl fumarate. It works by activating a transcription factor called NRF2, which activates a cascade of pathways that protect the cell from damage. There is also data suggesting that it may work in additional ways some of which are anti-inflammatory. BG12 is not immunosuppressive; i.e. people on the drug are not at risk of opportunistic infections the best indicator that the drug is not immunosuppressive. For BG12 to be used in combination will require specific trials and data; at the moment there are no combination trials underway.

    ReplyDelete
  7. Is the post that showed up in Google Reader about Mouse Doc true? If so, is there anything we can do? Email campaign?

    ReplyDelete
  8. This comment has been removed by the author.

    ReplyDelete
  9. I don't know how my comment was removed by me- I wasn't online at the time, and I don't think it was that controversial

    I think there is an EXPLORE trial NCT 01156311 into BG 12 as an add on to injectibles.

    If you'd had alemtuzumab would BG12 still be seen as an add on therapy 5,10,15 years post treatment if BG 12 proves to be an effective neuroprotective agent? I know some people have been treated with alemtuzumab when they've continued to relapse with tysabri, which I would've thought was more of a hit to the immune system.

    ReplyDelete
  10. Re: "Is it wise to exercise during a relapse? Exercising is supposed to be beneficial for MS but the fatigue also brings on fresh symptoms. So is it advisable?"

    No. There is animal data that shows that when a demyelinated axon is over-active in an inflammatory environment it is more likely to die. We therefore advise not over doing it during a relapse and waiting for recovery to start. Obviously this will depend on where the lesion is and how severe the relapse is. Let common sense rule the day; a relapse with numbness and pins-and-needles over the upper arm is very different to a relapse that causes weakness of a leg.

    ReplyDelete
  11. Re: "BG12 as an add-on


    Yes you are correct; please see:
    http://clinicaltrials.gov/ct2/show/NCT01156311?term=fumarate&lead=Biogen-Idec&rank=3

    This trial, however, is an add-on safety study and is not powered to assess efficacy. These trials are needed to assess safety if the drug was added on when it is licensed.

    ReplyDelete
  12. Anonymous said...
    Biogen Idec, CEO Scangos Pay Reached $11.3 Million in 2011. It is more profitable being a Pharma CEO than being a banker; MS is obviously a profitable disease for some people.

    http://www.biospace.com/News/biogen-idec-inc-massachusetts-ceo-scangos-pay/254397/source=TopBreaking


    So buy some shares and complain about this.

    ReplyDelete

Please note that all comments are moderated and any personal or marketing-related submissions will not be shown.